Cardiff Oncology (CRDF) Competitors $2.64 +0.27 (+11.39%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.66 +0.02 (+0.61%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDF vs. AMPH, MENS, IOVA, ELVN, AVXL, GPCR, ARDX, COLL, BGM, and VERVShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Amphastar Pharmaceuticals (AMPH), Jyong Biotech (MENS), Iovance Biotherapeutics (IOVA), Enliven Therapeutics (ELVN), Anavex Life Sciences (AVXL), Structure Therapeutics (GPCR), Ardelyx (ARDX), Collegium Pharmaceutical (COLL), BGM Group (BGM), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical products" industry. Cardiff Oncology vs. Its Competitors Amphastar Pharmaceuticals Jyong Biotech Iovance Biotherapeutics Enliven Therapeutics Anavex Life Sciences Structure Therapeutics Ardelyx Collegium Pharmaceutical BGM Group Verve Therapeutics Amphastar Pharmaceuticals (NASDAQ:AMPH) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment. Do insiders and institutionals have more ownership in AMPH or CRDF? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 27.5% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to AMPH or CRDF? In the previous week, Cardiff Oncology had 9 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 19 mentions for Cardiff Oncology and 10 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.87 beat Cardiff Oncology's score of 0.48 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Which has preferable valuation & earnings, AMPH or CRDF? Amphastar Pharmaceuticals has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$731.97M1.37$159.52M$2.767.68Cardiff Oncology$680K258.29-$45.43M-$0.87-3.03 Is AMPH or CRDF more profitable? Amphastar Pharmaceuticals has a net margin of 19.38% compared to Cardiff Oncology's net margin of -9,344.14%. Amphastar Pharmaceuticals' return on equity of 22.20% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals19.38% 22.20% 10.40% Cardiff Oncology -9,344.14%-77.94%-63.65% Which has more volatility and risk, AMPH or CRDF? Amphastar Pharmaceuticals has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Do analysts recommend AMPH or CRDF? Amphastar Pharmaceuticals currently has a consensus price target of $32.33, indicating a potential upside of 52.44%. Cardiff Oncology has a consensus price target of $11.70, indicating a potential upside of 343.18%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryAmphastar Pharmaceuticals beats Cardiff Oncology on 10 of the 16 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDF vs. The Competition Export to ExcelMetricCardiff OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.67M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-3.0317.6228.6723.80Price / Sales258.29179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book3.008.508.275.55Net Income-$45.43M-$55.06M$3.24B$259.03M7 Day Performance-33.50%-3.98%-3.69%-4.59%1 Month Performance-26.46%9.59%4.33%4.46%1 Year Performance17.86%6.72%25.95%18.03% Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDFCardiff Oncology1.787 of 5 stars$2.64+11.4%$11.70+343.2%+14.3%$157.67M$680K-3.0320Trending NewsEarnings ReportInsider TradeOptions VolumeAnalyst RevisionGap UpHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.3834 of 5 stars$22.24-0.6%$32.33+45.4%-50.0%$1.05B$731.97M8.062,028News CoverageUpcoming EarningsMENSJyong BiotechN/A$14.48+4.9%N/AN/A$1.05BN/A0.0031Positive NewsQuiet Period ExpirationIOVAIovance Biotherapeutics4.4473 of 5 stars$2.95-5.8%$12.22+314.3%-67.2%$1.05B$164.07M-2.38500Upcoming EarningsGap DownELVNEnliven Therapeutics2.4608 of 5 stars$20.67-2.5%$41.20+99.3%-24.2%$1.04BN/A-10.7750AVXLAnavex Life Sciences3.6596 of 5 stars$11.57-4.6%$44.00+280.3%+70.2%$1.04BN/A-21.0440News CoverageUpcoming EarningsHigh Trading VolumeGPCRStructure Therapeutics2.0502 of 5 stars$18.27+1.8%$76.17+316.9%-51.7%$1.03BN/A-21.00136News CoverageUpcoming EarningsARDXArdelyx4.0654 of 5 stars$4.28-0.2%$10.89+154.4%-21.3%$1.03B$333.61M-19.4590News CoverageUpcoming EarningsCOLLCollegium Pharmaceutical4.0387 of 5 stars$31.36-1.3%$43.75+39.5%-22.1%$1.02B$631.45M25.70210Upcoming EarningsBGMBGM GroupN/A$10.04-3.9%N/AN/A$1.02B$25.10M0.00298VERVVerve Therapeutics3.3594 of 5 stars$11.13flat$14.57+30.9%N/A$992.16M$32.33M-5.27110News Coverage Related Companies and Tools Related Companies AMPH Competitors MENS Competitors IOVA Competitors ELVN Competitors AVXL Competitors GPCR Competitors ARDX Competitors COLL Competitors BGM Competitors VERV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDF) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDF Stock Alerts